

Indexed in Pub Med, Med Line, Science Direct, Elsevier, etc.

ISSN 1302-2656

Volume 35, No. 1, 2011

TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES



An Official Journal of the Turkish Pharmaceutical Association, Academy of Pharmacy

Editorial Board

Editor in Chief

Prof. Terken BAYDAR, Ph.D., E.R.T.

ORCID: orcid.org/0000-0002-5497-9600

Hacettepe University, Faculty of Pharmacy, Department of Toxicology, Ankara, TURKEY

E-mail: tbaydar@hacettepe.edu.tr

Associate Editors

Prof. Samiye YABANOĞLU ÇİFTÇİ, Ph.D.

ORCID: orcid.org/0000-0001-5467-0497

Hacettepe University, Faculty of Pharmacy, Department of Biochemistry, Ankara, TURKEY

E-mail: samiye@hacettepe.edu.tr

Assoc. Prof. Pınar ERKEKOĞLU, Ph.D.

ORCID: orcid.org/0000-0003-4713-7672

Hacettepe University, Faculty of Pharmacy, Department of Toxicology, Ankara, TURKEY

E-mail: erkekp@hacettepe.edu.tr

Editorial Board

Prof. Fernanda BORGES, Ph.D.

ORCID: orcid.org/0000-0003-1050-2402

Porto University, Faculty of Sciences, Department of Chemistry and Biochemistry, Porto,
PORTUGAL

E-mail: fborges@fc.up.pt

Prof. Bezhan CHANKVETADZE, Ph.D.

ORCID: orcid.org/0000-0003-2379-9815

Ivane Javakhishvili Tbilisi State University, Institute of Physical and Analytical Chemistry, Tbilisi,
GEORGIA

E-mail: jpba_bezhan@yahoo.com

Prof. Dietmar FUCHS, Ph.D.

ORCID: orcid.org/0000-0003-1627-9563

Innsbruck Medical University, Center for Chemistry and Biomedicine, Institute of Biological

Chemistry, Biocenter, Innsbruck, AUSTRIA

E-mail: dietmar.fuchs@i-med.ac.at

Prof. Satyajit D. Sarker, Ph.D.

ORCID: orcid.org/0000-0003-4038-0514

Liverpool John Moores University, Liverpool, UNITED KINGDOM

E-mail: S.Sarker@ljmu.ac.uk

Prof. Luciano SASO, Ph.D.

ORCID: orcid.org/0000-0003-4530-8706

Sapienze University, Faculty of Pharmacy and Medicine, Department of Physiology and Pharmacology "Vittorio Erspamer", Rome, ITALY

E-mail: luciano.saso@uniroma1.it

Prof. Rob VERPOORTE, Ph.D.

ORCID: orcid.org/0000-0001-6180-1424

Leiden University, Natural Products Laboratory, Leiden, NETHERLANDS

E-mail: verpoort@chem.leidenuniv.nl

Advisory Board

Prof. Nurettin ABACIOĞLU, Ph.D.

Kyrenia University, Faculty of Pharmacy, Department of Pharmacology, Girne, TRNC, CYPRUS

Prof. Kadriye BENKLİ, Ph.D.

Girne American University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Girne, TRNC, CYPRUS

Prof. Arzu BEŞİKÇİ, Ph.D.

Ankara University, Faculty of Pharmacy, Department of Pharmacology, Ankara, TURKEY

Prof. Erem BİLENSOY, Ph.D.

Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, TURKEY

Prof. Hermann BOLT, Ph.D.

Dortmund University, Leibniz Research Centre, Institute of Occupational Physiology, Dortmund, GERMANY

Prof. Erdal CEVHER, Ph.D.

Istanbul University Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TURKEY

Prof. Nevin ERK, Ph.D.

Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, Ankara, TURKEY

Prof. Jean-Alain FEHRENTZ, Ph.D.

Montpellier University, Faculty of Pharmacy, Institute of Biomolecules Max Mousseron, Montpellier, FRANCE

Prof. Joerg KREUTER, Ph.D.

Johann Wolfgang Goethe University, Faculty of Pharmacy, Institute of Pharmaceutical Technology, Frankfurt, GERMANY

Prof. Christine LAFFORGUE, Ph.D.

Paris-Sud University, Faculty of Pharmacy, Department of Dermopharmacology and Cosmetology, Paris, FRANCE

Prof. Şule APİKOĞLU RABUŞ, Ph.D.

Marmara University, Faculty of Pharmacy, Department of Clinical Pharmacy, Istanbul, TURKEY

Prof. Robert RAPOPORT, Ph.D.

Cincinnati University, Faculty of Pharmacy, Department of Pharmacology and Cell Biophysics, Cincinnati, USA

Prof. Wolfgang SADEE, Ph.D.

Ohio State University, Center for Pharmacogenomics, Ohio, USA

Prof. Hildebert WAGNER, Ph.D.

Ludwig-Maximilians University, Center for Pharmaceutical Research, Institute of Pharmacy, Munich, GERMANY

Assoc. Prof. Hande SİPAHI, Ph.D.

Yeditepe University, Faculty of Pharmacy, Department of Toxicology, Istanbul, TURKEY

Assoc. Prof. İpek SÜNTAR, Ph.D.

Gazi University, Faculty of Pharmacy, Department of Pharmacognosy, Ankara, TURKEY

Letter to Editor

Can Pharmacists be More Effective Regarding the Proper Use of Face Masks by the Public During the COVID-19 Pandemic?

 [Nesliğül ÖZDEMİR](#)  [Melda BAHAP](#)  [Ayçe ÇELİKER](#)

Turk J Pharm Sci 2020; 17: 357-358 DOI: 10.4274/tjps.galenos.2020.58997 PMID:32939129

Original Article

Development and Statistical Optimization of Solid Lipid Nanoparticle Formulations of Fluticasone Propionate

 [Gülin AMASYA](#)  [Ceyda Tuba ŞENGEL TÜRK](#)  [Uluya BADILLI](#)  [Nilüfer TARIMCI](#)

Turk J Pharm Sci 2020; 17: 359-366 DOI: 10.4274/tjps.galenos.2019.27136 PMID:32939130

Evaluation of Lactose-Based Direct Tableting Agents' Compressibility Behavior Using a Compaction Simulator

 [Yıldız ÖZALP](#)  [Motunrayo M. ONAYO](#)  [Nailla JIWA](#)

Turk J Pharm Sci 2020; 17: 367-371 DOI: 10.4274/tjps.galenos.2019.94840 PMID:32939131

Determining the Best Poloxamer Carrier for Thiocolchicoside Solid Dispersions

 [Hemanth ANNEPOGU](#)  [Hindustan Abdul AHAD](#)  [Devanna NAYAKANTI](#)

Turk J Pharm Sci 2020; 17: 372-380 DOI: 10.4274/tjps.galenos.2019.78800 PMID:32939132

The Formulation of Methylene Blue Encapsulated, Tc-99m Labeled Multifunctional Liposomes for Sentinel Lymph Node Imaging and Therapy

 [Mine SİLİNDİR GÜNAY](#)

Turk J Pharm Sci 2020; 17: 381-387 DOI: 10.4274/tjps.galenos.2019.86619 PMID:32939133

Development of Bioadhesive Buccal Tablets of Nicorandil Using a Factorial Approach

 [Rajendra KOTADIYA](#)  [Karan SHAH](#)

Turk J Pharm Sci 2020; 17: 388-397 DOI: 10.4274/tjps.galenos.2019.09226 PMID:32939134

Electrochemical Determination of Rifampicin Based on Its Oxidation Using Multi-Walled Carbon Nanotube-Modified Glassy Carbon Electrodes

 [Dilek KUL](#)

Turk J Pharm Sci 2020; 17: 398-407DOI: 10.4274/tjps.galenos.2019.33600PMID:32939135

Investigation of the Peripheral Analgesic Activity of Oxicams and Their Combinations with Caffeine

 [Anna SYROVA](#)  [Larisa LUKYANOVA](#)  [Svetlana KOZUB](#)  [Oksana ZAVADA](#)  [Olga LEVASHOVA](#)  [Viktor SHAPOSHNIK](#)

Turk J Pharm Sci 2020; 17: 408-411DOI: 10.4274/tjps.galenos.2019.92063PMID:32939136

Green Synthesis and Characterization of Copper Nanoparticles and Their Effects on Liver Function and Hematological Parameters in Mice

 [Mehrdad KHATAMI](#)  [Katrin EBRAHIMI](#)  [Nasrin GALEHDAR](#)  [Mohammad Nabi MORADI](#)  [Alireza MOAYYEDKAZEMI](#)

Turk J Pharm Sci 2020; 17: 412-416DOI: 10.4274/tjps.galenos.2019.28000PMID:32939137

Molecular Docking Simulation Studies of Curcumin and Its Derivatives as Cyclin-Dependent Kinase 2 Inhibitors

 [Riyadi SUMIRTANURDIN](#)  [Shafira SUNGKAR](#)  [Yasarah HISPRASTIN](#)  [Kenny Dwi SIDHARTA](#)  [Dea Dian NURHIKMAH](#)

Turk J Pharm Sci 2020; 17: 417-423DOI: 10.4274/tjps.galenos.2019.55822PMID:32939138

Ferulic Acid Prevents Angiogenesis Through Cyclooxygenase-2 and Vascular Endothelial Growth Factor in the Chick Embryo Chorioallantoic Membrane Model

 [Juni EKOWATI](#)  [Iwan Sahrial HAMID](#)  [Nuzul Wahyuning DIYAH](#)  [Siswando SISWANDONO](#)

Turk J Pharm Sci 2020; 17: 424-431DOI: 10.4274/tjps.galenos.2019.44712PMID:32939139

Safety Assessment of Vanillic Acid: Subacute Oral Toxicity Studies in Wistar Rats

 [Anwarbaig Chandbaig MIRZA](#)  [Shital Sharad PANCHAL](#)

Turk J Pharm Sci 2020; 17: 432-439DOI: 10.4274/tjps.galenos.2019.92678PMID:32939140

The Effect of *Rusa unicolor* Antler Deer Extracts from East Kalimantan in Bone Turnover Cell Models

 Retno WIDYOWATI  Suciati SUCIATI  Dewi Melani HARYADI  Hsin-I CHANG
 IPG Ngurah SURYAWAN  Agung Widi UTAMA

Turk J Pharm Sci 2020; 17: 440-445DOI: 10.4274/tjps.galenos.2019.57805PMID:32939141

Cytotoxic, Genotoxic, and Apoptotic Effects of Nickel Oxide Nanoparticles in Intestinal Epithelial Cells

 Mahmoud ABUDAYYAK  Elif GÜZEL  Gül ÖZHAN

Turk J Pharm Sci 2020; 17: 446-451DOI: 10.4274/tjps.galenos.2019.76376PMID:32939142

Evaluation of the Possible Role of miRNAs in Chemical Allergen Potency

 Hatice Gül ANLAR  Valentina GALBIATI  Emanuela CORSINI  Nurşen BAŞARAN

Turk J Pharm Sci 2020; 17: 452-456DOI: 10.4274/tjps.galenos.2019.25349PMID:32939143

Toxicological Evaluation of Bisphenol A and Its Analogues

 İrem İYİGÜNDOĞDU  Aylin ÜSTÜNDAĞ  Yalçın DUYDU

Turk J Pharm Sci 2020; 17: 457-462DOI: 10.4274/tjps.galenos.2019.58219PMID:32939144



Ferulic Acid Prevents Angiogenesis Through Cyclooxygenase-2 and Vascular Endothelial Growth Factor in the Chick Embryo Chorioallantoic Membrane Model

Ferulik Asitin Tavuk Embriyo Koriyoallantoik Membran Modelinde Siklooksijenaz 2 ve Vasküler Endotel Büyüme Faktörü Üzerinden Anjiyojenezi Önlemesi

✉ Juni EKOWATI^{1*}, ✉ Iwan Sahrial HAMID², ✉ Nuzul Wahyuning DIYAH¹, ✉ Siswandono SISWANDONO¹

¹Airlangga University Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Surabaya, Indonesia

²Airlangga University Faculty of Veterinary Medicine, Department of Basic Veterinary Medicine, Surabaya, Indonesia

ABSTRACT

Objectives: This study was designed to verify the antiangiogenic activity of ferulic acid (FA) and its potency to inhibit cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) expression in the chorioallantoic membrane (CAM) model. Moreover, we verified its mechanism of action by docking the molecule on COX-2, tyrosine kinase, and VEGF-2 proteins *in silico*.

Materials and Methods: An antiangiogenesis assay of FA at doses of 30, 60, and 90 µg was performed using the CAM of chicken eggs that were 9 days old and stimulated by 60 ng of basic fibroblast growth factor. Celecoxib (60 µg) was used as the reference drug. The inhibitory activity on VEGF and COX-2 expression was determined by immunohistochemistry assay. Molecular docking of FA was accomplished by Molegro Virtual Docker program ver. 5.5 on COX-2 enzyme (PDB ID 1CX2), tyrosine kinase receptor (PDB ID 1XKK), and VEGF-2 receptor (PDB ID 4ASD).

Results: FA at doses of 30, 60, and 90 µg significantly prevented angiogenesis in the CAM model, which was represented as inhibitory activity against endothelial cells of blood vessels (42.6–70.7%) and neovascularization (43.0–86.6%). The inhibitory activity of FA against VEGF expression was stronger than its action on COX-2 expression. Molecular docking on VEGF-2 receptor resulted in an RS value of FA of -73.844 kcal/mol and for celecoxib it was -94.557 kcal/mol. The RS value on tyrosine kinase of FA was -84.954 kcal/mol, while on celecoxib it was -93.163 kcal/mol. Docking on COX-2 receptor gave an RS value of FA of -73.416 kcal/mol, while for celecoxib it was -118.107 kcal/mol.

Conclusion: Reductions in VEGF-2 and COX-2 expression due to treatment with FA at the dose range 30–90 µg appeared to be related to angiogenesis inhibition, which was shown by two parameters, namely inhibition of neovascularization and endothelial cell growth in blood vessels. It was concluded that FA is a promising antiangiogenic therapeutic agent especially at the early stage, and this activity can arise from inhibitory action on COX-2 and VEGF-2 proteins.

Key words: Ferulic acid, COX-2, VEGF, tyrosine kinase, angiogenesis, chorioallantoic membrane

ÖZ

Amaç: Bu çalışma ferulik asidin (FA)'nın koriyoallantoik membran (CAM) modelinde antianjiyojenik aktivitesini ve siklooksijenaz-2 (COX-2) ve vasküler endotel büyüme faktörünü (VEGF) inhibe etme potensinin doğrulamak üzere tasarlanmıştır.

Gereç ve Yöntemler: FA'nın antianjiyojenik testi dokuz günlük olan ve 3 ng bazik fibroblast faktörü ile stimüle edilen tavuk yumurtalarının CAM'ına 30, 60 ve 90 µg uygulanarak gerçekleştirilmiştir. Referans ilaç olarak selekoksib (60 µg) kullanılmıştır. VEGF ve COX-2 üzerindeki inhibitor aktivitesi immünohistokimya yöntemi ile gerçekleştirilmiştir. FA'nın moleküler kenetlenmesi Molegro Virtual Docker program ver. 5.5 ile COX-2 enzimi (PDB ID 1CX2), tirozin kinaz reseptörü (PDB ID 1XKK) ve VEGF-2 reseptörü (PDB ID 4ASD) üzerinde gerçekleştirilmiştir.

*Correspondence: E-mail: juni-e@ff.unair.ac.id, Phone: +081332041503 ORCID-ID: orcid.org/0000-0002-4402-2039

Received: 04.12.2018, Accepted: 04.04.2019

©Turk J Pharm Sci, Published by Galenos Publishing House.

Bulgular: FA 30, 60 ve 90 µg dozlarında CAM modelinde belirgin bir şekilde anjiyogenezin önlenmiş ve kan damarlarının endotel hücrelerine karşı inhibitör aktivite (%42,6–%70,7) ve neovaskülarizasyon (%43,0–%86,6) göstermiştir. FA'nın VEGF ekspresyonuna karşı inhibitör aktivitesi COX-2 ekspresyonuna karşı olan etkisinden daha güçlü bulunmuştur. FA için VEGF-2 reseptörüne moleküler kenetlenme RS değeri -73,844 kcal/mol ve selekoksib için -94,557 kcal/mol'dür. FA'nın tirozin kinaz üzerine RS değeri -84,954 kcal/mol iken selekoksib üzerine -93,163 kcal/mol'dür. FA'nın COX-2 reseptörü üzerine kenetlenmesinde RS değeri -73,416 kcal/mol iken, selekoksib üzerine kenetlenme değeri -118,107 kcal/mol'dür.

Sonuç: 30-90 µg aralığında FA uygulaması ile VEGF-2 ve COX-2 ekspresyonlarında görülen azalmalar anjiyogenezin inhibisyonuna ilişkili olarak görülmektedir ve bu 2 parametre (neovaskülarizasyon ve kan damarlarında endotel hücre büyümesinin inhibisyonu) ile gösterilmiştir. Sonuç olarak FA'nın özellikle erken evrede ümit vaat eden antiangiyojenik terapötik bir ajan olduğu söylenebilir ve bu aktivite COX-2 ve VEGF-2 proteinleri üzerindeki inhibitör etkisinden kaynaklanıyor olabilir.

Anahtar kelimeler: Ferulik asit, COX-2, VEGF, tirozin kinaz, anjiyogenez, koryoallantoik membran

INTRODUCTION

The progression of cancer cells depends heavily on angiogenesis, the formation of new blood vessels that supply oxygen and food required for the tumor's cell proliferation and metastasis progression.^{1,2} The development of cancer cells is induced by angiogenesis, which is activated by some growth factors such as vascular endothelial growth factor receptor (VEGFR). Two important growth factor receptors that influence angiogenesis are tyrosine kinase receptor (TKR) and VEGFR-2.^{1,3}

The VEGF signaling pathway is a strategic target for angiogenesis inhibitors.^{4,5} However, there are some clinical problems involving angiogenesis inhibitors in patients (i.e. thromboembolic disorders, intracranial hemorrhage, and bowel perforation).⁶ Other problems are the occurrence of toxicities such as bleeding, fatigue, hypertension, and perforation of the gastrointestinal tract.^{7,8} Therefore, the study of a new antiangiogenic substance that is relatively safe in its pharmaceutical dosage form is an important step in cancer treatment.

Ferulic acid (FA) [3-(4-hydroxy-3-methoxyphenyl)-2-propenoic acid] (Figure 1) is a phenolic acid compound that shows antioxidant^{9,10} and cytotoxic activities in many cancer cell lines.^{11,12} Wang et al.¹³ reported that FA could inhibit the proliferation and induced apoptosis of osteosarcoma cells via the PI3K/Akt pathway. FA also had anti-inflammatory activity and inhibited cyclooxygenase-2 (COX-2) enzyme,¹⁴ which were related to angiogenesis.^{2,15} Koki and Masferrer¹⁶ reported that COX-2 expression increased during the tumorigenesis process and the intensity of its expression was in line with the degree of carcinogenesis. Wu et al.¹⁷ reported that the biosynthesis of PG catalyzed by COX-2 could stimulate the VEGF expression in tumor cells and acted as a positive feedback loop between tumor cells and endothelial cells.

In an effort to improve FA as a drug candidate for cancer chemoprevention, we studied its antiangiogenic activity and inhibitory activity against COX-2 and VEGF expression in the chicken egg chorioallantoic membrane (CAM) model. The CAM assay is a robust and applicable technique to assess a potential drug candidate. The assay has been commonly used to study angiogenesis and tumor invasion in various types of cancer.^{18,19} To verify FA's mechanism in the inhibition of angiogenesis, we conducted molecular docking on COX-2 enzyme, tyrosine kinase, and VEGF-2 receptors.

MATERIALS AND METHODS

Materials

Commercially available materials were used as obtained. FA, Tris-HCl, and basic fibroblast growth factor (bFGF) were purchased from Sigma-Aldrich (St Louis, MO, USA). The chicken eggs were collected from PUSVETMA Surabaya, Indonesia.

Chorioallantoic membrane assay

Twenty-five 9-day-old chicken eggs were incubated at 37°C (60–70% humidity) for 1 day. All of the treatment groups of CAMs were induced by bFGF at a concentration of 1 ng/µL in Tris-HCl solution of pH 7.5. The eggs were divided into five groups; each group consisted of six eggs. Three groups were treated with FA at doses of 30, 60, and 90 µg; the positive control group was treated with celecoxib (60 µg) and one group received no treatment, which was set as the negative control. The egg was perforated to make a hole 1 cm² in diameter to remove the air. Sterile Whatman filter-paper disks 5 mm in diameter with tested compound and bFGF or bFGF alone were dropped into the hole and then were impregnated into the CAM of each embryo. The hole was covered and the egg returned to incubation at 37°C (60% humidity) for 72 h. After incubation, the upper eggshell was opened and the presence of neovascularization from the main blood vessels onto the paper disks was recorded. In addition, we also collected the blood vessels of the CAM in formalin buffer and carried out microscopic observations of the histopathologic slide of the CAM using hematoxylin and eosin staining. To confirm the antiangiogenic activity, this CAM assay was achieved with certain alteration as explained before.^{18,20} The growth of the endothelial cells in the neovascular capillaries was exposed in CAM cross-sections by an inverted phase contrast microscope, a Nikon H600L. The number of endothelial cells in five graphical fields were calculated, whereas each slide was observed at 400x amplification and compared with the positive or negative control groups for the following analysis.

Antibodies

Rabbit polyclonal anti-human COX-2 and VEGF antibodies were obtained from Thermo Scientific™ Lab Vision™ (St Louis, MO, USA).

Immunohistochemical assay

The slides for the immunohistochemical assay were prepared at the Laboratory of Anatomical Pathology, Dr. Sardjito Hospital, Yogyakarta, Indonesia. Paraffin blocks of the CAM

containing blood vessels were cut 3–4 μm thick and placed on the poly-lysine slide, and then they were incubated overnight at 45°C. The next step of VEGF or COX-2 staining for the immunohistochemical assay was carried out as reported in previous research.^{16,19} In the present study, we used Mayer's hematoxylin for counterstaining. Tris-EDTA solution at pH 9 was used in the retrieval step of VEGF staining for 15–20 min, whereas pH 6 citrate buffer was used for retrieval of COX-2 staining for 15–20 min. The slides were divided into six groups. One group consisted of slides of CAM expressing COX-2 protein, which was used as the positive control; three groups contained slides of FA at doses of 30, 60, and 90 μg , one group contained slides of celecoxib at a dose of 60 μg , which was used as the reference drug; and one group was used as a negative control group. The microscopic observation of VEGF expression and COX-2 expression was continued by counting the visible brown cells in five fields for a minimum of 100 cells. This assay was approved by the Ethical Commission of Airlangga University, but it did not involve human participants.

Statistical analysis

The data obtained were subjected to ANOVA and a One-Way Fisher exact test at 95% level of confidence. If there was significant variance among each group, the analysis was continued with Duncan's multiple range test. Statistical significant was set at $p < 0.05$. All statistical analyses were presented using IBM SPSS 21.

Molecular docking equipment

Hardware: Laptop ASUS AMD A8 Vision with CPU @1.9 GHz, 4 GB of RAM.

Software: CS ChemDraw Ultra version 12.00 (Cambridge Soft) was utilized to create the three-dimensional structure (3D) of FA, which was then subjected to energy minimization by MMFF94 method and the 3D structure was saved in SYBYLMol2 format (*.Mol2). Molegro Virtual Docker (MVD) version 5.5 (CLC Bio) was employed as a docking program in this research. The 3D structures of COX-2, TKR, and VEGF-2 proteins were downloaded from the Internet (<http://www.rcsb.org/pdb/home/home.do>)

In silico assay

The 3D structures of the three proteins, which were obtained from a protein data bank (PDB), were: 1) 1XKK, which was TKR containing *N*-(3-chloro-4-[(3-fluorobenzyl)oxy]phenyl)-6-[4-quinazolinamine) (code FMM-901) as reference ligand, 2) 4ASD, which was VEGFR-2 containing sorafenib (BAX 43-9006) as reference ligand, and (3) 1CX2, which was COX-2 containing [4-(5-(4-bromophenyl)-3-(trifluoro-methyl)-1H-pyrazole-1yl)benzenesulfonamide) (SC58)] as reference ligand. Ligand-protein interactions were prepared by FA molecule MVD version software 5.5. Docking of the FA molecule into each of the 3D structures of proteins was performed as described in our previous study.²⁰ The best docking results can be observed by relating the structure of the docked FA molecule to the crystal structure of the reference ligand at the binding site. The docking results were presented as a rerank score (RS), which

was the total free energy of the ligand-protein interaction. The lowest energy indicated the best pose of binding between the functional group of ligand and amino acid residues of the proteins. The ligand-protein complexes of the lowest score (RS) were used for further visual inspection. The validation of the docking result was performed by redocking the reference ligand into the same cavity in each protein. The redocking result was accepted if the root mean square deviation $< 2.0 \text{ \AA}$.

RESULTS AND DISCUSSION

Antiangiogenic activity of ferulic acid

The antiangiogenesis assay is performed on the CAM of the embryonated chicken egg because the membrane is the site of very high vascularization and is easily observable in line with the process of chicken embryo growth.^{18,21} The CAM is a fusion of chorion and allantois of chicken egg membrane formed after 4 days of incubation.¹⁸ The formation of new blood vessels is derived from the capillaries that arise from the blood vessels.

Angiogenesis in the CAM model through macroscopic observations of new blood vessels induced by bFGF was significantly inhibited ($p < 0.05$) by FA at doses of 30, 60, and 90 μg . The results are represented by inhibition of neovascularization (Figure 2).

Neovascularization is inseparable from the preceding mechanism of growth and the formation of new endothelial cells, whereas one of the angiogenesis stages is endothelial cell migration.²² At this stage, the capillary walls of the blood vessels continue their growth into the lumen of other blood vessels. There are four phases of migration: the growth of two opposite capillary walls, the joining of regulated endothelial cells and bending of the bilayer facilitate growth factors so the cells enter the lumen, and the center of angiogenesis is




Figure 1. Ferulic acid




Figure 2. A) Capillary of neovascularization of CAM induced by 60 μg of bFGF (blue arrow) in control positive group, B) capillary of neovascularization of CAM induced by 60 ng of bFGF and treated with 60 μg of celecoxib (black arrow), C) capillary of neovascularization of CAM induced by 60 μg of bFGF and treated with 60 μg of FA (black arrow)

CAM: Chorioallantoic membrane, bFGF: Basic fibroblast growth factor, FA: Ferulic acid

formed between the new blood vessels filled by pericytes and myofibroblasts. The center of angiogenesis is the appearance of smooth muscle fibers that complement the formation of new blood vessels with the development of hematopoiesis as early vascularization.

Figure 2 shows several capillary blood vessels progressing into the impregnated disk of the group without treatment. After treatment with FA and celecoxib, there was a decrease in the number of new blood vessels around the disk on the CAM and endothelial cells of blood vessels. The percentages of inhibition of neovascularization and endothelial cell growth of blood vessels are shown in Table 1.

Based on the statistical analysis by one-way ANOVA, followed by Duncan's multiple range test, it is known that there is no significant difference in potency of the inhibition of neovascularization between celecoxib at 60 μg dose and FA at 60-90 μg dose ($p < 0.05$). However, the potency of FA at 30 μg is smaller than that of FA at 60-90 μg , whereas the potency of FA at 90 μg dose to inhibit endothelial cells of blood vessels is stronger than that of FA at 30-60 μg dose. No significant differences were seen in the potency of inhibition of endothelial cells of blood vessels between FA at 90 μg dose and celecoxib at 60 μg dose ($p < 0.05$). As a reference drug, celecoxib (60 μg) provided 83% new blood vessel growth inhibition in the CAM model.

Ferulic acid inhibited VEGF and COX-2 expression

The microscopic image of VEGF expression in the endothelial cells of the new blood vessels belonging to the positive control group is dominated by the presence of a brown color. It is in sharp contrast to an image from the negative control group, which displays a dominant blue color in the endothelial cell cytoplasm. The brown color in the cytoplasm indicates that VEGF expression of the endothelial cells treated by FA decreases with increasing dose of the substance from 30 μg to 90 μg . The microscopic observation results of VEGF expression in each treatment group are presented in Figure 3.

The microscopic observation results of COX-2 expression in each treatment group are presented in Figure 4. All data of the treatment group are presented in Table 2 and analyzed by SPSS version 21.0 for Windows.

Analysis of percentage inhibition of VEGF expression by FA using the one-sample Kolmogorov-Smirnov test for normality showed probability of $p = 0.398$, whereas percentage inhibition

of COX-2 expression with the one-sample Kolmogorov-Smirnov test showed probability of $p = 0.458$. This means the data are normally distributed because p is greater than 0.05 ($p > 0.05$). Based on statistical analysis by One-Way ANOVA, continued




Figure 3. VEGF expression within endothelial cells of blood vessels of the CAM, 400 times magnification: A) positive control group (blank treatment with 60 μg of bFGF), B) group of 60 μg celecoxib treatment, C) group of 60 μg FA treatment, D) group of 90 μg FA treatment. Arrows indicate there is VEGF expression

VEGF: Vascular endothelial growth factor, CAM: Chorioallantoic membrane, bFGF: Basic fibroblast growth factor, FA: Ferulic acid




Figure 4. COX-2 expression within endothelial cells of blood vessels of the CAM, 400 times magnification: A) positive control group (blank treatment with 60 μg of bFGF), B) group of 60 μg celecoxib treatment, C) group of 60 μg FA treatment, D) group of 90 μg FA treatment. Arrows indicate there is COX-2 expression

COX-2: Cyclooxygenase-2, CAM: Chorioallantoic membrane, bFGF: Basic fibroblast growth factor, FA: Ferulic acid

Table 1. Antiangiogenesis activity in the CAM model in each group

Treatment	% inhibition of neovascularization	% inhibition of endothelial cells
Celecoxib 60 μg	83.3 ^b ±5.2	79.3 ^c ±2.3
FA 30 μg	43.0 ^a ±4.6	42.6 ^a ±5.9
FA 60 μg	83.4 ^b ±7.4	57.3 ^b ±4.3
FA 90 μg	86.6 ^b ±6.2	70.7 ^c ±3.9

All values are represented as the mean \pm SE (n=6) and different superscripts in the same column indicate that there were significant different in each group ($p < 0.05$)
FA: Ferulic acid, CAM: Chorioallantoic membrane, SE: Standard error

with LSD and Duncan's multiple range tests, it is known that there is no significant difference in the potency of inhibition of VEGF expression between celecoxib at 60 µg dose and FA at 60-90 µg dose ($p < 0.05$). The potency of FA inhibiting VEGF expression at 30 µg to 90 µg was dose-dependent. Increasing dose of FA resulted in decreasing VEGF expression of CAM significantly.

Based on the data in Table 2, it is known that giving 30-90 µg of FA decreases VEGF expression in CAM significantly. Reduced VEGF expression due to treatment with FA at 30-90 µg doses is in line with angiogenesis inhibition, which is shown by two parameters, namely neovascularization and resistance to endothelial cell growth of blood vessels in the chick embryo CAM.

The main VEGF receptor in endothelial cells is VEGFR-2, which influences developing and adult cells. VEGFR-2 signaling is better recognized than the other VEGF receptors' signaling. Vascular permeability is an essential *in vivo* consequence of VEGFR-2 activation. Several small-molecular-weight inhibitors of VEGFR-2 kinase activity are employed clinically to block pathological angiogenesis in cancer.¹³

In vitro experiments on capillary endothelial cells showed that VEGF is a powerful stimulator against the occurrence of angiogenesis. This is due to its presence as a growth factor triggering the proliferation and migration of endothelial cells, even the formation of tube formation in a series of capillary vessels.²³ Inhibition of VEGF can occur in several ways; the first is inhibition at the VEGF receptor through kinase activity that contributes to the delivery of growth signals. The second possibility is inhibition through endothelial cell apoptosis induction, whereas the third may involve the incorporation of hematopoiesis and endothelial progenitor cells, and so VEGF is not capable of triggering vasculogenesis.²⁴

According to Di Marco et al.²⁵, binding of VEGFR and VEGF-specific ligand occurs in the transmembrane and cytoplasmic domains. VEGF is known as a promoter of angiogenesis and an endogenous regulator of endothelial integrity. Some anti-VEGF compounds can cause endothelial dysfunction and decreased angiogenesis.

The COX-2 expression in the CAM also presented a brown color in the cell cytoplasm, which is a ligand-receptor complex of COX-2 detected by anti-COX-2 antibodies that are specifically bound to COX-2 ligand. Based on the data in Table 2, it is known that treatment with 30-90 µg of FA can significantly decrease COX-2 expression in the CAM. The inhibitory activity of FA against COX-2 expression is dose-dependent. The inhibitory potency of FA at dose range 30-90 µg is significantly different from that of celecoxib at the 60 µg dose. In our study, the administration of FA appeared to play an important role in angiogenesis inhibition through decreasing COX-2 expression.

The reduction in COX-2 expression due to treatment with FA at the dose range 30-90 µg seems to have been related to angiogenesis inhibition, which is shown by two parameters, namely inhibition of neovascularization and inhibition of endothelial cell growth in blood vessels of chick embryo CAM. Hsu et al.²⁶ reported that prostaglandin-E2 (PGE2) stimulates COX-2 expression in LoVo colon cancer cells. The COX2 expression was interrelated with the elevation in the migration ability of those cancer cells. The experimental data suggested that PGE2 can be a potential therapeutic target in colon cancer metastasis. Yao et al.²⁷ stated that downregulation of COX-2 could significantly diminish the progression of gastric cancer cells and block the replacement and tube formation of human umbilical vein endothelial cells. The results also indicated that downregulation of COX-2 might inhibit VEGF.

Table 2. Inhibition of VEGF and COX-2 expression in the CAM model in each group

Treatment	% inhibition of VEGF expression	% inhibition of COX-2 expression
Celecoxib 60 µg	72.9±6.8 ^b	84.1±4.2 ^c
FA 30 µg	46.7±8.0 ^a	49.9±6.3 ^a
FA 60 µg	63.7±4.9 ^b	55.0±4.6 ^a
FA 90 µg	73.6±5.3 ^b	66.8±2.8 ^b

All values are represented as the mean ± SE (n=6) and different superscripts in the same column indicate that there were significant differences in each treatment ($p < 0.05$)

VEGF: Vascular endothelial growth factor, COX-2: Cyclooxygenase-2, CAM: Chorioallantoic membrane, FA: Ferulic acid

Table 3. The rerank score, type of bonding interactions, and amino acids involved in the interaction of ligands with VEGFR-2 (PDB ID 4ASD)

Compound	Rerank score (kcal/mol)	Number of H-bonds	Amino acid residue	Number of steric interactions	Amino acid residue
FA	-73.844	1	Glu885	6	Ala1050, Glu885, Leu 889, Val 848
Celecoxib	-94.557	2	Gln847 Lys868	24	Asn1033, Cys1045, Gln847, Glu885, Lys868, Phe1047, Val848, Val867, Val914

VEGFR-2: Vascular endothelial growth factor receptor-2, FA: Ferulic acid, Glu: Glutamine, Ser: Serine, Leu: Leucine, Tyr: Tyrosine, Val: Valine, Phe: Phenylalanine

The COX-2 inhibitor celecoxib²⁸ has been reported to inhibit the growth of prostate, gastric, lung, and breast cancer.^{29,30} The induction of bFGF as pro-angiogenic compounds will lead to inflammation associated with the COX-2 activity.^{31,32} As well as celecoxib, FA also inhibited COX-2 enzyme^{14,30} and so it could obstruct bFGF activity as a pro-angiogenic compound.

Based on the inhibitory mechanism of angiogenesis through the inhibition of VEGF expression examined by other researchers in several studies, it is possible that FA inhibits VEGFR-2 through its inhibitory activity on tyrosine kinase and COX-2. This assumption is studied and proven through *in silico* docking on COX-2, TKR, and VEGFR-2.

Docking study

The best-docked pose of FA, celecoxib, and BAX ligands in the binding site of VEGFR-2 and the interactions between functional groups of FA and celecoxib with amino acid residues in two-dimensional (2D) structures are shown in Figure 5. The docking scores (RS value), the type of bonding interactions with VEGFR-2, and amino acids involved in their interactions are listed in Table 3.

The best-docked pose of FA, celecoxib, and native ligand in the binding site of tyrosine kinase and their interactions with amino acid residues in 2D structures are shown in Figure 6. The RS value, the type of interactions, and amino acids involved in the interaction between ligand and TKR are listed in Table 4.

The ligand of PDB ID 1XKK contains a benzylic group (Ar-C-), which acts as a pharmacophore in the ligand-receptor interaction complex. The FA compound contains a similar group, which is also expected to be a pharmacophore. Celecoxib, which produces a lower RS value than FA (Table 3), displays more H-bonds and steric interactions with TKR than FA.

The best-docked pose of FA, celecoxib, native ligand in the binding site of COX-2 and their interactions with amino acid residues of each protein in 2D structures are shown in Figures 5-7. The RS value, the type of bonding interactions with COX-2, and amino acids involved in their interactions are listed in Table 5.

Based on the molecular docking study, the possible interactions can be explained between each compound, i.e. FA and celecoxib, with amino acid residues in each protein enzyme/receptor. The FA-TKR interaction is stronger than FA-VEGFR-2, indicating the possibility that FA worked on growth factor receptors,^{1,31} and it is apparent that FA inhibited VEGF expression in the CAM model.

The ligand binding of VEGFR stimulated strong tyrosine phosphorylation and results in an intense angiogenesis response.³¹ Replacement of the native ligand of VEGFR-2 with FA through the interactions of functional groups of FA with the amino acid residue of VEGFR-2 prevented tyrosine phosphorylation and so decreased angiogenesis.³²




Figure 5. The best docking of FA (yellow)-celecoxib (blue)-BAX (green) ligands A); the three ligands positioned at the active site (cavity-2) of VEGFR-2 B); interaction of celecoxib with amino acids in cavity-2 of VEGFR-2 C); interaction of FA with amino acids in cavity-2 of VEGFR-2 D) FA: Ferulic acid, VEGFR-2: Vascular endothelial growth factor receptor-2




Figure 6. The best docking of FA (yellow)-celecoxib (blue)-FMM (green) A); the three ligands positioned at the active site (cavity-1) of TKR; B); interaction of celecoxib with amino acids of TKR C); interaction of FA with amino acids of TKR D), PDB 1XKK FA: Ferulic acid, TKR: Tyrosine kinase receptor

Table 4. The rerank score, type of bonding interactions, and amino acids involved in the interaction of ligands with TKR (PDB 1XKK)

Compound	Rerank score (kcal/mol)	Number of H-bonds	Amino acid residue	Number of steric interactions	Amino acid residue
FA	-84.954	1	Lys745	9	Ala743, Gly796, Leu792, Leu844, Lys745, Met793, Val726
Celecoxib	-93.163	2	Met793	24	Ala743, Asp855, Gln791, Leu792, Leu844, Lys745, Met793

TKR: Tyrosine kinase receptor, FA: Ferulic acid, Lys: Lysine, Met: Methionine, Asp: Aspartic Ala: Alanine, Gly: Glutamine, Ser: Serine, Leu: Leucine, Tyr: Tyrosine, Val: Valine

Table 5. The rerank score, type of bonding interactions, and amino acids involved in the interaction of ligands with COX-2 (PDB 1CX2)

Compound	Rerank score (kcal/mol)	Number of H-bonds	Amino acid residue	Number of steric interactions	Amino acid residue
FA	-73.416	3	Ser353, His90	3	Tyr355, Val523, Leu352
Celecoxib	-118.107	5	Arg513 His90 Ser353 Leu352 Gln152	16	Tyr355, Val523, Val349, Ser530, Val116, Ser353, Leu352, Phe518

COX-2: Cyclooxygenase-2, FA: Ferulic acid, Ser: Serine, Arg: Arginine, His: Histidine, Leu: Leucine, Gln: Glutamine, Tyr: Tyrosine, Phe: Phenylalanine, Val: Valine




Figure 7. The best docking of FA (yellow)-celecoxib (blue)-SC58 (green) A); the three ligands positioned at the active site (cavity-3) of COX-2 B); the interaction of celecoxib with amino acids COX-2 C); interaction of FA with amino acids COX-2 D), PDB 1CX2

FA: Ferulic acid, COX-2: Cyclooxygenase-2

There are several phases of angiogenesis inhibition, i.e. prevention of endogenous angiogenic factors such as bFGF and VEGF; inhibition of the degradation matrix metalloproteinase (MMP), reducing endothelial cell proliferation; and prevention of endothelial cell movement, inhibiting endothelial cell activation and differentiation.³³

Based on the data and description above, the mechanisms by which FA prevents angiogenesis are by blocking COX-2 activity so that MMP activity, which plays a role in the early formation of branching of blood vessels, will stop, and by obstructing endogenous angiogenic factors, i.e. VEGF and bFGF, in the initial stage of angiogenesis.

Study limitations

In our study, FA inhibits angiogenesis in the CAM model in the earliest process, i.e. endogenous angiogenic factors and kinase activity promoting release of growth signals. Thus, the potency of FA to inhibit angiogenesis at other stages needs further research.

CONCLUSION

FA (at a dose of 30–90 µg) is a promising antiangiogenic therapeutic agent, especially in an early stage of angiogenesis. It prevents proangiogenic growth factor, which leads to

inflammation (i.e. bFGF), activity of MMP, and development of branching of blood vessels. This activity results from inhibitory action on COX-2 and VEGF-2 proteins.

Conflicts of interest: All authors declare that they have no competing interests.

Financial Disclosure: Publication of this article was funded by PTUPT Grant Airlangga University 2017/2018.

REFERENCES

- Roskoski R. Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. *Biochem Biophys Res Commun.* 2007;356:323-328.
- Sahin M, Sahin E, Gümüslü S. Cyclooxygenase-2 in cancer and angiogenesis. *Angiology.* 2015;60:242-253.
- Bikfalvi A, Moenner M, Javerzat S, North S, Hagedorn M. Inhibition of angiogenesis and the angiogenesis/invasion shift. *Biochem Soc Trans.* 2011;39:1560-1564.
- Saha S, Islam MK, Shilpi JA, Hasan S. Inhibition of VEGF: a novel mechanism to control angiogenesis by Withania som-nifera's key metabolite Withaferin A. *In Silico Pharmacol.* 2013;1:11.
- Taylor M, Coleman RL, Sood AK. The Role of Angiogenesis in Cancer. *Target Ther Transl Cancer Res.* 2015:64-71.
- Newton HB. Bevacizumab: Review of Development, Pharmacology, and Application to Brain Tumors. *Clin Med Ther.* 2009;1:1577-1597.
- Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? *Angiogenesis.* 2010;13:1-14.
- Altun A, Temiz TK, Balci E, Polat ZA, Turan M. Effects of tyrosine kinase inhibitor E7080 and eNOS inhibitor L-NIO on colorectal cancer alone and in combination. *Chin J Cancer Res.* 2013;25:572-584.
- Graf E. Antioxidant potential of ferulic acid. *Free Radic Biol Med.* 1992;13:435-448.
- Itagaki S, Kurokawa T, Nakata C, Saito Y, Oikawa S, Kobayashi M, Hirano T, Iseki K. *In vitro* and *in vivo* antioxidant properties of ferulic acid: A comparative study with other natural oxidation inhibitors. *Food Chem.* 2009;114:466-471.
- Peng CC, Chyau CC, Wang HE, Chang CH, Chen KC, Chou KY, Peng RY. Cytotoxicity of ferulic acid on T24 cell line differentiated by different microenvironments. *Biomed Res Int.* 2013;2013:579859.
- Senawong T, Khaopha S, Misuna S, Komaikul J, Senawong G, Wongphakham P, Yunchalard S. Phenolic acid composition and anticancer activity against human cancer cell lines of the commercially available fermentation products of *Houttuynia cordata*. *Science Asia.* 2014;40:420-427.

13. Wang L, Chen W, Xie X, He Y, Bai X. Celecoxib Inhibits Tumor Growth and Angiogenesis in an Orthotopic Implantation Tumor Model of Human. *Exp Oncol*. 2008;30:42-51.
14. Nile SH, Ko EY, Kim DH, Keum YS. Screening of ferulic acid related compounds as inhibitors of xanthine oxidase and cyclooxygenase-2 with anti-inflammatory activity. *Brazilian J Pharmacogn* 2016, 26:50-5. Available from: <http://dx.doi.org/10.1016/j.bjp.2015.08.013>
15. Rosas C, Sinning M, Ferreira A, Fuenzalida M, Lemus D. Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. *Biol Res*. 2014;47:1-9.
16. Koki AT, Masferrer JL. Celecoxib: A specific COX-2 inhibitor with anticancer properties. *Cancer Control*. 2002;9(Suppl 2):28-35.
17. Wu GF, Luo J, Rana JS, Laham R, Sellke FW, Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. *Cardiovasc Res*. 2006;69:512-519.
18. Ribatti D. The chick embryo chorioallantoic membrane as an *in vivo* assay to study antiangiogenesis. *Pharmaceuticals (Basel)*. 2010;3:482-513.
19. Yuan YJ, Xu K, Wu W, Luo Q, Yu JL. Application of the chick embryo chorioallantoic membrane in neurosurgery disease. *Int J Med Sci*. 2014;11:1275-1281.
20. Ekowati J, Hardjono S, Hamid IS. Ethyl p -methoxycinnamate from *Kaempferia galanga* inhibits angiogenesis through tyrosine kinase. *Universa Med*. 2015;34:43-51.
21. Richardson M, Wong D, Lacroix S, Stanis.z J, Singh G. Inhibition by doxycycline of angiogenesis in the chicken chorioallantoic membrane (CAM). *Cancer Chemother Pharmacol*. 2005;56:1-9.
22. Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance. *Dev Dyn*. 2004;231:474-488.
23. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. *J Clin Oncol*. 2005;23:254-266.
24. Kuwano T, Nakao S, Yamamoto H, Tsuneyoshi M, Yamamoto T, Kuwano M, Ono M. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. *FASEB J*. 2004;18:300-310.
25. Di Marco GS, Reuter S, Hillebrand U, Amler S, König M, Langer E, Oberleithner H, Brand E, Pavenstädt H, Brand M. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. *J Am Soc Nephrol*. 2009;20:2235-2245.
26. Hsu HH, Lin YM, Shen CY, Shibu MA, Li SY, Chang SH, Lin CC, Chen RJ, Viswanadha VP, Shih HN, Huang CY. Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells. *Int J Mol Sci*. 2017;18:1132.
27. Yao L, Liu F, Hong L, Sun L, Liang S, Wu K, Fan D. The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. *J Exp Clin Cancer Res*. 2011;30:13.
28. Klenke FM, Gebhard MM, Ewerbeck V, Abdollahi A, Huber PE, Sckell A. The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice. *BMC Cancer*. 2006;6:9.
29. Moschona A, Kyriakidis KD, Kleontas AD, Liakopoulou-M. Comparative Study of Natural Phenolic Acids and Flavonols as Antiplatelet and Anti-Inflammatory Agents. *The Grant Med J*. 2017;2:57-66.
30. Manoharan S, Rejitharaji T, Prabhaka MM, Manimaran A, Sing RB. : Modulating Effect of Ferulic Acid on NF-kB, COX-2 and VEGF Expression Pattern During. 7,12-Dimethylbenz(a)anthracene Induced Oral Carcinogenesis. *The Open Nutraceuticals Journal*. 2014;7:33-38.
31. Schmidt U, Ahmed J, Michalsky E, Hoepfner M, Preissner R. Comparative Vegf Receptor Tyrosine Kinase Modeling for the Development of Highly Specific Inhibitors of Tumor Angiogenesis. *Genome Inform*. 2008;20:243-251.
32. Jeltsch M, Leppanen VM, Saharinen P, Alitalo K. Receptor Tyrosine Kinase-Mediated Angiogenesis. *Cold Spring Harb Perspect Biol*. 2013;5:a009183.
33. Stegmann TJ, Hoppert T, Schneider A, Popp M, Strupp G, Ibing RO, Hertel A. Therapeutic Angiogenesis : Intramyocardial Growth Factor Delivery of FGF-1 as Sole Therapy in Patients with Chronic Coronary Artery Disease:1-14. Available from: <https://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.577.9796&rep=rep1&type=pdf>